Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES FRY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology with Special Qualifications in Child Neurology

NPI
1659482305
CMS profile
347967
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$39,781.51

213 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES FRY

NPI 1659482305 · CMS profile ID 347967

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659482305?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES FRY, NPI 1659482305, CMS profile ID 347967. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659482305?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JAMES FRY, NPI 1659482305, CMS profile ID 347967. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659482305?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JAMES FRY, NPI 1659482305, CMS profile ID 347967, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659482305?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

213 matching records · $39,781.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 213 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 213.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Supernus Pharmaceuticals, Inc. $1,750.0008/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038409 CMS
Supernus Pharmaceuticals, Inc. $284.0208/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038413 CMS
Supernus Pharmaceuticals, Inc. $14.9808/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038417 CMS
Neurocrine Biosciences, Inc. $125.0008/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837791121 CMS
Supernus Pharmaceuticals, Inc. $1,750.0008/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038371 CMS
Supernus Pharmaceuticals, Inc. $397.1508/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038375 CMS
Supernus Pharmaceuticals, Inc. $17.0308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038377 CMS
Supernus Pharmaceuticals, Inc. $1,750.0008/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038383 CMS
Supernus Pharmaceuticals, Inc. $397.1608/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038387 CMS
Supernus Pharmaceuticals, Inc. $25.1908/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038389 CMS
SK Life Science, Inc. $20.8108/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826823533 CMS
Ironshore Pharmaceuticals Inc. $12.8108/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840375189 CMS
Supernus Pharmaceuticals, Inc. $4.7008/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038367 CMS
AQUESTIVE THERAPEUTICS, INC. $2.6908/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847837927 CMS
AQUESTIVE THERAPEUTICS, INC. $2.6908/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847837929 CMS
Adlon Therapeutics L.P. $20.2708/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844829739 CMS
Neurocrine Biosciences, Inc. $16.9108/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837791119 CMS
Neurelis, Inc. $14.2008/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842864925 CMS
SK Life Science, Inc. $7.8007/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826823513 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.1307/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819929849 CMS
Supernus Pharmaceuticals, Inc. $23.1707/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038363 CMS
AQUESTIVE THERAPEUTICS, INC. $23.1207/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847837845 CMS
Supernus Pharmaceuticals, Inc. $17.7307/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038359 CMS
AQUESTIVE THERAPEUTICS, INC. $14.6507/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847837789 CMS
Supernus Pharmaceuticals, Inc. $7.6807/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038355 CMS
SK Life Science, Inc. $168.9207/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826823509 CMS
Ironshore Pharmaceuticals Inc. $16.6007/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840375301 CMS
Neurocrine Biosciences, Inc. $9.7407/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837791117 CMS
SK Life Science, Inc. $23.0007/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826823511 CMS
Greenwich Biosciences, Inc. $20.9007/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841841051 CMS
SK Life Science, Inc. $4.4107/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826823515 CMS
Supernus Pharmaceuticals, Inc. $7.7607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038347 CMS
Supernus Pharmaceuticals, Inc. $1.6207/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038351 CMS
Neurelis, Inc. $16.3307/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842864917 CMS
Neurelis, Inc. $2.1507/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842864921 CMS
Supernus Pharmaceuticals, Inc. $4.3206/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038343 CMS
Adlon Therapeutics L.P. $14.0706/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844829735 CMS
SK Life Science, Inc. $5.8606/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826823507 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.5006/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819929847 CMS
Greenwich Biosciences, Inc. $117.2206/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841841083 CMS
Supernus Pharmaceuticals, Inc. $4.7006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038339 CMS
Supernus Pharmaceuticals, Inc. $2.9906/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038335 CMS
Eisai Inc. $14.5906/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817938387 CMS
Ironshore Pharmaceuticals Inc. $22.6906/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840375181 CMS
Neurelis, Inc. $1.6406/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842864909 CMS
Neurelis, Inc. $18.2206/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842864913 CMS
Greenwich Biosciences, Inc. $23.4406/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841841037 CMS
Supernus Pharmaceuticals, Inc. $3.1706/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845038331 CMS
Neurocrine Biosciences, Inc. $10.4705/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837791115 CMS
SK Life Science, Inc. $16.5205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826823501 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,417.44 147
PY2020 $2,053.44 130
PY2021 $39,781.51 213
PY2022 $15,320.10 154
PY2023 $3,071.55 135
PY2024 $3,117.61 110
PY2025 $2,137.08 83

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,655.26 1
PY2025 Principal investigator $618,284.00 292
PY2024 Principal investigator $793,921.73 174
PY2023 Recipient $13,768.75 8
PY2023 Principal investigator $533,434.70 82
PY2022 Principal investigator $437,790.54 56
PY2021 Principal investigator $45,219.05 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

293 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 years of age. No dispute reported 06/30/2026 1202532356
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202535021
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202535023
Principal investigator 1 ABBVIE INC. $673.76 12/31/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age No dispute reported 06/30/2026 1202535025
Principal investigator 1 ABBVIE INC. $750.00 12/31/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202535271
Principal investigator 1 ABBVIE INC. $39.50 12/31/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202535273
Principal investigator 1 ABBVIE INC. $39.50 12/31/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202535319
Principal investigator 1 ABBVIE INC. $100.00 12/24/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202532056
Principal investigator 1 ABBVIE INC. $11.87 12/24/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202532058
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $70.00 12/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242369439
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $203.00 12/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242369441
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,597.00 12/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242369443
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $700.00 12/17/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242369205
Principal investigator 1 ABBVIE INC. $11.87 12/11/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202530136
Principal investigator 1 ABBVIE INC. $39.50 12/11/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202530232
Principal investigator 1 ABBVIE INC. $78.99 12/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202529760
Principal investigator 1 ABBVIE INC. $2,866.25 12/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202528090
Principal investigator 1 ABBVIE INC. $4,863.00 12/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202528092
Principal investigator 1 ABBVIE INC. $45.64 12/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202528566
Principal investigator 1 ABBVIE INC. $45.64 12/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202528670
Principal investigator 1 ABBVIE INC. $9,720.00 12/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202528684
Principal investigator 1 ABBVIE INC. $9,521.25 12/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202528760
Principal investigator 1 ABBVIE INC. $45.64 12/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202528762
Principal investigator 1 ABBVIE INC. $200.00 12/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202526294
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $39.50 12/01/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242367887
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $750.00 12/01/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242367889
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $250.00 12/01/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242367907
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,981.00 11/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366951
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,344.00 11/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366953
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,329.00 11/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366955
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,977.00 11/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366957
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,223.00 11/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366959
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,329.00 11/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366961
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,223.00 11/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366963
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,329.00 11/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366965
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,103.00 11/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366967
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $70.00 11/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242366467
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,597.00 11/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242366469
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $203.00 11/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242366471
Principal investigator 1 ABBVIE INC. $32.60 11/18/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202524555
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.64 11/17/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242366063
Principal investigator 1 ABBVIE INC. $108.00 11/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202524205
Principal investigator 1 ABBVIE INC. $100.00 11/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202524207
Principal investigator 1 ABBVIE INC. $735.00 11/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202524221
Principal investigator 1 ABBVIE INC. $100.00 11/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202523673
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $700.00 11/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242365861
Principal investigator 1 ABBVIE INC. $1,955.00 11/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202522587
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $75.40 11/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242365337
Principal investigator 1 ABBVIE INC. $31.87 11/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202520803
Principal investigator 1 ABBVIE INC. $2,064.00 11/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202520805
Principal investigator 1 ABBVIE INC. $5,269.00 11/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202520807
Principal investigator 1 ABBVIE INC. $31.87 11/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520833
Principal investigator 1 ABBVIE INC. $9,000.00 11/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520835
Principal investigator 1 ABBVIE INC. $12,538.75 11/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520837
Principal investigator 1 ABBVIE INC. $29.02 11/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202520947
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $25.35 11/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242365115
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 11/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242365117
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $65.20 11/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242365119
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $65.19 11/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242365155
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $22.82 11/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242365269
Principal investigator 1 ABBVIE INC. $22.82 10/29/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202519633
Principal investigator 1 ABBVIE INC. $45.64 10/28/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202518727
Principal investigator 1 ABBVIE INC. $50.71 10/23/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202518229
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,143.00 10/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242364409
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $132.00 10/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242364411
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 10/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242364413
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 10/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242364415
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 10/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242364417
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,143.00 10/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242364419
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $132.00 10/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242364421
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 10/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242364423
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 10/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242364425
Principal investigator 1 ABBVIE INC. $313.00 10/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202517689
Principal investigator 1 ABBVIE INC. $313.00 10/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202517691
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $895.00 10/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242363987
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $895.00 10/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242363989
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,056.00 10/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242363991
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $83.00 10/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242363993
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,056.00 10/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242363995
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,329.00 10/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242363997
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,977.00 10/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242363999
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $83.00 10/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242364001
Principal investigator 1 ABBVIE INC. $26.56 10/14/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202516621
Principal investigator 1 ABBVIE INC. $53.12 10/14/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516731
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $31.09 10/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242363739
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $53.11 10/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242363761
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $25.35 10/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242363765
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $750.00 10/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242363781
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $31.87 10/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242363783
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 10/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242363393
Principal investigator 1 ABBVIE INC. $2,450.00 10/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202513789
Principal investigator 1 ABBVIE INC. $750.00 10/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202513791
Principal investigator 1 ABBVIE INC. $2,163.00 10/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202513793
Principal investigator 1 ABBVIE INC. $11.87 10/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202513795
Principal investigator 1 ABBVIE INC. $7,580.00 10/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202513977
Principal investigator 1 ABBVIE INC. $2,227.50 10/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202513979
Principal investigator 1 ABBVIE INC. $3,781.25 10/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516379
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,922.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242359836
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $83.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242359838
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $52.68 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242359914
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $400.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242359916
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $895.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242360312
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,056.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242360314
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,329.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242360316
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,977.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242360318
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,223.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242360320
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,329.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242360322
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,103.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242360324
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $83.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242360326
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,922.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361839
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $83.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361841
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361843
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361845
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $83.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361847
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361849
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $83.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361851
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361853
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,833.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361855
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361857
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361859
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361861
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,833.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361863
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361865
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361867
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361869
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,223.00 10/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242361871
Principal investigator 1 ABBVIE INC. $37.71 09/30/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202512826
Principal investigator 1 ABBVIE INC. $37.70 09/30/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202512828
Principal investigator 1 ABBVIE INC. $31.09 09/26/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202512498
Principal investigator 1 ABBVIE INC. $52.67 09/26/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202512500
Principal investigator 1 ABBVIE INC. $52.68 09/17/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202511204
Principal investigator 1 ABBVIE INC. $26.33 09/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202510330
Principal investigator 1 ABBVIE INC. $31.09 09/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202510156
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 09/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242358598
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,000.00 09/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242358600
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $700.00 09/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242358602
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,000.00 09/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242358604
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,052.00 09/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-321 No dispute reported 06/30/2026 1242358606
Principal investigator 1 ABBVIE INC. $3,170.00 09/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202509116
Principal investigator 1 ABBVIE INC. $31.09 09/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202509256
Principal investigator 1 ABBVIE INC. $750.00 09/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202509258
Principal investigator 1 ABBVIE INC. $15,693.75 09/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202507661
Principal investigator 1 ABBVIE INC. $11,633.75 09/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202507715
Principal investigator 1 ABBVIE INC. $2,663.00 09/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202507717
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $100.00 09/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242358236
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $100.00 09/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242358238
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $52.68 09/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242358240
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $750.00 09/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242358346
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $700.00 09/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242358348
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $26.34 08/25/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242358172
Principal investigator 1 ABBVIE INC. $175.10 08/21/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202505465
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,922.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357424
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357426
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,143.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357428
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $132.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357430
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357432
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357434
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357436
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,223.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357438
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $83.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357440
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 08/20/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357442
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $149.10 08/18/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242357318
Principal investigator 1 ABBVIE INC. $210.00 08/14/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202504835
Principal investigator 1 ABBVIE INC. $74.09 08/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202503895
Principal investigator 1 ABBVIE INC. $49.39 08/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202503927
Principal investigator 1 ABBVIE INC. $11.26 08/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202503953
Principal investigator 1 ABBVIE INC. $15,235.00 08/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501838
Principal investigator 1 ABBVIE INC. $108.00 08/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202501840
Principal investigator 1 ABBVIE INC. $11,010.00 08/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501842
Principal investigator 1 ABBVIE INC. $4,076.00 08/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202501934
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $49.40 07/28/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242355524
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $49.39 07/28/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242355526
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,250.00 07/28/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242355528
Principal investigator 1 ABBVIE INC. $750.00 07/24/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202499520
Principal investigator 1 ABBVIE INC. $313.00 07/23/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202499308
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,833.00 07/23/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242355086
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 07/23/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242355088
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 07/23/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242355090
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,080.00 07/23/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242355092
Principal investigator 1 ABBVIE INC. $148.14 07/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202499066
Principal investigator 1 ABBVIE INC. $313.00 07/16/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202498368
Principal investigator 1 ABBVIE INC. $29.63 07/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202497836
Principal investigator 1 ABBVIE INC. $750.00 07/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202497850
Principal investigator 1 ABBVIE INC. $10.99 07/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202497868
Principal investigator 1 ABBVIE INC. $49.38 07/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202498024
Principal investigator 1 ABBVIE INC. $29.63 07/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202498038
Principal investigator 1 ABBVIE INC. $29.63 07/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202498040
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $700.00 07/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242352562
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $750.00 07/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242352564
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 07/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242352570
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $100.00 07/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242352636
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $49.38 07/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242352670
Principal investigator 1 ABBVIE INC. $13,542.50 07/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202494469
Principal investigator 1 ABBVIE INC. $8,758.75 07/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202494471
Principal investigator 1 ABBVIE INC. $5,514.00 07/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202494595
Principal investigator 1 ABBVIE INC. $1,600.00 07/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202494701
Principal investigator 1 ABBVIE INC. $11,507.50 07/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202496671
Principal investigator 1 ABBVIE INC. $29.64 07/01/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202493717
Principal investigator 1 ABBVIE INC. $49.39 07/01/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202493763
Principal investigator 1 ABBVIE INC. $29.64 07/01/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202493765
Principal investigator 1 ABBVIE INC. $4,921.25 07/01/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202493849
Principal investigator 1 ABBVIE INC. $10.99 07/01/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202493851
Principal investigator 1 ABBVIE INC. $21.00 07/01/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202493853
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,922.00 06/25/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242351998
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,922.00 06/25/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242352000
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,223.00 06/25/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242352002
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $83.00 06/25/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242352004
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 06/25/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242352006
Principal investigator 1 Eli Lilly and Company $42,705.85 06/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187875681
Principal investigator 1 ABBVIE INC. $18.10 06/12/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202491005
Principal investigator 1 ABBVIE INC. $37.04 06/12/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202491343
Principal investigator 1 ABBVIE INC. $36.20 06/12/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202491367
Principal investigator 1 ABBVIE INC. $111.14 06/12/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202491369
Principal investigator 1 ABBVIE INC. $21.00 06/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202490681
Principal investigator 1 ABBVIE INC. $148.18 06/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202490127
Principal investigator 1 ABBVIE INC. $313.00 06/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202490129
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $98.79 06/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242348732
Principal investigator 1 ABBVIE INC. $2,227.50 06/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202487337
Principal investigator 1 ABBVIE INC. $1,450.00 06/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202489563
Principal investigator 1 ABBVIE INC. $313.00 06/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202489565
Principal investigator 1 ABBVIE INC. $3,539.00 06/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202489567
Principal investigator 1 ABBVIE INC. $10,283.75 06/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202489799
Principal investigator 1 ABBVIE INC. $74.58 05/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202485747
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,000.00 05/19/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242347572
Principal investigator 1 ABBVIE INC. $500.00 05/14/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202484795
Principal investigator 1 ABBVIE INC. $59.67 05/14/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202484797
Principal investigator 1 ABBVIE INC. $29.84 05/14/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202484799
Principal investigator 1 ABBVIE INC. $29.83 05/14/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202484803
Principal investigator 1 ABBVIE INC. $29.83 05/14/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202484869
Principal investigator 1 ABBVIE INC. $2,227.50 05/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202482403
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,052.00 05/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242346643
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,000.00 05/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
ITI-007-601 No dispute reported 06/30/2026 1242346659
Principal investigator 1 ABBVIE INC. $15,782.50 05/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481121
Principal investigator 1 ABBVIE INC. $3,413.00 05/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202481123
Principal investigator 1 ABBVIE INC. $10.99 05/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481135
Principal investigator 1 ABBVIE INC. $4,227.00 05/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202481155
Principal investigator 1 ABBVIE INC. $3,132.00 05/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202480923
Principal investigator 1 ABBVIE INC. $74.12 04/24/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202479364
Principal investigator 1 ABBVIE INC. $10.99 04/23/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202478583
Principal investigator 1 ABBVIE INC. $74.11 04/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202475777
Principal investigator 1 ABBVIE INC. $10.99 04/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202475931
Principal investigator 1 ABBVIE INC. $74.12 04/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202475957
Principal investigator 1 ABBVIE INC. $10.99 04/10/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202476041
Principal investigator 1 ABBVIE INC. $6,677.00 04/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202471530
Principal investigator 1 ABBVIE INC. $1,680.00 04/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202471534
Principal investigator 1 ABBVIE INC. $8,682.00 04/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202471537
Principal investigator 1 ABBVIE INC. $8,542.50 04/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202473497
Principal investigator 1 ABBVIE INC. $10.99 04/03/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202473699
Principal investigator 1 ABBVIE INC. $30.66 03/27/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202466550
Principal investigator 1 ABBVIE INC. $98.79 03/27/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202466563
Principal investigator 1 ABBVIE INC. $34.23 03/27/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202466811
Principal investigator 1 ABBVIE INC. $49.39 03/27/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202467025
Principal investigator 1 Eli Lilly and Company $207.06 03/19/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187873195
Principal investigator 1 ABBVIE INC. $73.81 03/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202462964
Principal investigator 1 ABBVIE INC. $9,150.00 03/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202463021
Principal investigator 1 ABBVIE INC. $73.80 03/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202463124
Principal investigator 1 ABBVIE INC. $800.00 03/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202463314
Principal investigator 1 ABBVIE INC. $12.66 03/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202463726
Principal investigator 1 ABBVIE INC. $10,052.00 03/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202459184
Principal investigator 1 ABBVIE INC. $147.61 03/07/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202461027
Principal investigator 1 ABBVIE INC. $7,078.00 03/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202456383
Principal investigator 1 ABBVIE INC. $5,169.00 03/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202457579
Principal investigator 1 ABBVIE INC. $26,762.50 03/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202457950
Principal investigator 1 ABBVIE INC. $313.00 03/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202458875
Principal investigator 1 ABBVIE INC. $313.00 03/06/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202458879
Principal investigator 1 ABBVIE INC. $147.47 03/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202455627
Principal investigator 1 ABBVIE INC. $42.84 03/04/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202455727
Recipient Eli Lilly and Company $1,655.26 03/04/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187871679
Principal investigator 1 ABBVIE INC. $34.23 02/27/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202454195
Principal investigator 1 ABBVIE INC. $100.00 02/27/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202454199
Principal investigator 1 ABBVIE INC. $30.66 02/27/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202454203
Principal investigator 1 ABBVIE INC. $73.74 02/18/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202452208
Principal investigator 1 ABBVIE INC. $73.73 02/18/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202452248
Principal investigator 1 ABBVIE INC. $23.58 02/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202450890
Principal investigator 1 ABBVIE INC. $74.98 02/13/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202450946
Principal investigator 1 ABBVIE INC. $49.16 02/12/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202450574
Principal investigator 1 ABBVIE INC. $13.44 02/12/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202450578
Principal investigator 1 ABBVIE INC. $2,000.00 02/12/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202450593
Principal investigator 1 ABBVIE INC. $49.15 02/12/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202450597
Principal investigator 1 ABBVIE INC. $74.97 02/12/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202450657
Principal investigator 1 ABBVIE INC. $4,665.00 02/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202443923
Principal investigator 1 ABBVIE INC. $19,972.50 02/05/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202444626
Principal investigator 1 ABBVIE INC. $10.99 01/30/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202443087
Principal investigator 1 ABBVIE INC. $10.99 01/22/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202440526
Principal investigator 1 ABBVIE INC. $73.74 01/16/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202439050
Principal investigator 1 ABBVIE INC. $73.73 01/16/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202439087
Principal investigator 1 ABBVIE INC. $36.16 01/16/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202439140
Principal investigator 1 ABBVIE INC. $10.99 01/16/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202439247
Principal investigator 1 ABBVIE INC. $195.00 01/15/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202438637
Principal investigator 1 ABBVIE INC. $32.97 01/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202437393
Principal investigator 1 ABBVIE INC. $98.91 01/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202437503
Principal investigator 1 ABBVIE INC. $10.99 01/09/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202437558
Principal investigator 1 ABBVIE INC. $34.23 01/02/2025 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202433909